Laura Hediger
Family · Springfield, MONPI 1316137128
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $59,806 of the $71,169 with a category attached, or 84.0%. 15 manufacturers reported payments, led by AbbVie at 48.8% of the total. Reporting peaked in 2021 at $28,315 and has fallen 69.3% since, to $8,687 in 2025. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 624 payments — averaging $114.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$35K
- Amgen$13K
- Biohaven Pharmaceuticals, Inc.$8K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- Pfizer$5K
- Lilly USA, LLC$1K
- plus $2K from 9 others
What the payments were for
- Consulting fees$1,0511%
- Speaking & faculty fees$59,80684%
- Travel & lodging$1,0832%
- Food & beverage$9,17113%
- Education$580%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 271 | $34,726 |
| Amgen | 30 | $12,759 |
| Biohaven Pharmaceuticals, Inc. | 50 | $8,269 |
| Biohaven Pharmaceutical Holding Company Ltd. | 56 | $7,832 |
| Pfizer | 76 | $4,747 |
| Lilly USA, LLC | 51 | $1,083 |
| Lundbeck LLC | 46 | $831 |
| Teva Pharmaceuticals USA, Inc. | 11 | $298 |
| Supernus Pharmaceuticals, Inc. | 21 | $218 |
| Axsome Therapeutics, Inc. | 1 | $123 |
| Dexcom, Inc. | 1 | $105 |
| Impel Pharmaceuticals Inc. | 4 | $58 |
| Ferring Pharmaceuticals Inc. | 4 | $54 |
| Amneal Pharmaceuticals LLC | 1 | $43 |
| Eisai Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$29,496
- NURTEC ODT$17,570
- AIMOVIG$12,354
- QULIPTA$11,127
- ZAVZPRET$1,080
- VYEPTI$136
- Auvelity$123
- MOUNJARO$108
- DEXCOM G7 GSS (161)$105
- DEXCOM STELO GLUCOSE BIOSENSOR$105
- AJOVY$102
How this compares
$71,169 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Emgality PenGalcanezumab-Gnlm | 244 | $258,270 |
| QuliptaAtogepant | 168 | $218,059 |
| UbrelvyUbrogepant | 156 | $180,913 |
| Nurtec OdtRimegepant Sulfate | 168 | $177,688 |
| Aimovig AutoinjectorErenumab-Aooe | 126 | $151,360 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 61 | $79,623 |
| Emgality SyringeGalcanezumab-Gnlm | 12 | $21,740 |
| Topiramate ErTopiramate | 23 | $8,834 |
| RizatriptanRizatriptan Benzoate | 298 | $5,629 |
| Sumatriptan | 25 | $3,818 |
| Baclofen | 180 | $3,365 |
| Tizanidine Hcl | 152 | $2,880 |
| Naratriptan Hcl | 52 | $2,169 |
| Ondansetron Hcl | 156 | $2,011 |
| Topiramate | 157 | $1,799 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $34,726 | $398,971324 claims |
| PfizerNurtec Odt | $4,747 | $177,688168 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Springfield
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
- Jordan PerezSaint Louis$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.